---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000098"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:22:24.189841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics reports Q2 net income $15.9M; initiates Phase 3 AURORA trial for Descartes-08 in MG

## Summary
- Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.
- Net income $15.9M ($0.51 basic EPS) vs $13.8M ($0.58 basic EPS) in Q2 2024.
- R&D expenses $14.9M, up from $12.7M, driven by Phase 3 AURORA trial costs.
- Preliminary Phase 2 data for Descartes-08 in SLE expected in 2H25; pediatric basket trial initiation also expected in 2H25.
- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis dosed first participant in May 2025; primary endpoint at Month 4.

## SEC filing metadata
- accession: 0001453687-25-000098
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000098/0001453687-25-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000098/rnac-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000098
- JSON: https://secwatch.observer/filing/0001453687-25-000098.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.